Evidence map›Paper›PMID 40255103›Full record

ArticleACS infectious diseases2025

Anti-SARS-CoV-2 Small Molecule Targeting of Oxysterol-Binding Protein (OSBP) Activates Cellular Antiviral Innate Immunity.

Bharathiraja Subramaniyan, Emily C Falcon, Andrew R Moore, Jason L Larabee, Susan L Nimmo, Jorge L Berrios-Rivera, William J Reddig, Earl L Blewett, James F Papin, Matthew S Walters and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Bharathiraja SubramaniyanDepartment of Medicine, Section of Pulmonary, Critical Care & Sleep Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Emily C FalconDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73117, United States.
Andrew R MooreDepartment of Medicine, Section of Pulmonary, Critical Care & Sleep Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Jason L LarabeeDepartment of Microbiology and Immunology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Susan L NimmoDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73117, United States.
Jorge L Berrios-RiveraDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73117, United States.
William J ReddigDepartment of Biochemistry and Microbiology, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma 74107, United States.
Earl L BlewettDepartment of Biochemistry and Microbiology, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma 74107, United States.
James F PapinDepartment of Pathology, Division of Comparative Medicine, University of Oklahoma Health Sciences Center, Oklahoma 73104, United States.
Matthew S WaltersDepartment of Medicine, Section of Pulmonary, Critical Care & Sleep Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States.
Anthony W G BurgettDepartment of Pharmaceutical Sciences, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73117, United States.ORCID 0000-0002-0685-5144

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI JUDITH A JAMES · 2013 to 2026
$68.2M
Pilot Project Grant ProgramP30GM149368 · NIGMS · OKLAHOMA STATE UNIVERSITY STILLWATER · PI LIN LIU · 2023 to 2026
$5.5M
NIGMS NIH HHS P30 GM149368NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

Human oxysterol-binding protein (OSBP) is a potentially druggable mediator in the replication of a broad spectrum of positive-sense (+) single-stranded RNA (ssRNA) viruses, including members of the

Indexed as

Antiviral AgentsCOVID-19 Drug TreatmentImmunity, InnateReceptors, SteroidSARS-CoV-2AnimalsCOVID-19HumansOxysterol Binding ProteinsVirus ReplicationAntiviral AgentsOxysterol Binding ProteinsReceptors, Steroidantiviral compoundsinnate antiviral immune responseOSW-1oxysterol-binding protein (OSBP)rhinovirusSARS-CoV-2

Identifiers

PMID40255103
PMCPMC12070403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.